ACIU
AC Immune SA
NASDAQ · Healthcare · Biotechnology · CH
$2.63
−1.87%Aug 5, 2026, 11:00 UTC
AC Immune initiated the Alzheimer's disease AD4 cohort in the ABATE trial, triggering a $12 million milestone payment from Takeda.
Source:Aug 5, 2026, 11:00 UTC
AC Immune reported financial results for the half-year ended June 30, 2026, with cash resources of CHF 75.4 million.
Source: